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In the event of malignancy skeletal involvement is common, 
being the third commonest site of metastatic disease after 
liver and lungs. Metastatic bone disease is associated with 
considerable morbidity and complications that may 
deteriorate the quality of life (QOL) of patients, reduce their 
functional capabilities and may even reduce overall survival.  
External beam RT is an established treatment modality for 
the management of bone metastases since decades, bringing 
about significant pain response and reduction in the skeletal 
complication rates. The effect of RT may be a result of the 
high level of inflammatory and tumor cell kill that is achieved 
and the consequent decrease in osteoclastic activity. 
Reossification and increased bone density in the area of 
metastatic bone lesions is considered to be an indication for 
successful treatment.  In the different published radiological 
response criteria (UICC, WHO and MDA) the level of re-
ossification describes the response classification. Importantly 
the level of reossification has been associated with an 
improved clinical response, a decreased level of suffering and 
pain, an Improved QOL and performance status and a 
decreased risk for pathologic fractures.  
Even though RT alone has shown to achieve significant 
increase in bone density in metastatic lesions, combination 
with other treatments such as Bps has shown to result in an 
enhanced level bone ossification (figure1). This is a result of 
the synergistic activity and common action of the two 
treatment modalities on osteoclasts that decreases their 
function and hinders bone destruction. Moreover the 
interruption of the vicious cycle enables osteoblasts to 
remodel and reossify ostoelytic lesions. This is associated 
with an improved therapeutic response and effectiveness. 
Moreover, a spatial cooperation is enabled, with RT 
controlling local bone lysis and Bps managing disease 
progression in skeletal regions away from the radiotherapy 
treatment field.  Enhanced ossification after the concomitant 
use of RT and Bps has also been shown in animal models. 
Notably their combined action was accompanied by an 
improved bone microarchitecture, bone volume and 
biomechanical strength.  
Denosumab has also shown to increase bone density and 
strength in patients with osteoporosis.  The effect is 
enhanced when combination treatment with teriparatide 
(recombinant form of parathyroid hormone) is used.  
In the published radiological response criteria bone density 
changes are not quantified.  This could be done by evaluating 
and measuring changes in Hounsfield units in the area of 
bone metastases. This may add to the overall treatment 
response assessment and help in determining the 
effectiveness of treatment. What is unquestionable is that 
remineralization is a very important endpoint that is an 
indication of a successful treatment. More over it was shown 
that it is accompanied by an improved clinical outcome, a 
reduction of possible skeletal complications and an improved 
bone microarchitecture and strength.   
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Figure one depicts the therapeutic outcome of a patient with 
breast cancer and a lytic lesion in the sacrum managed with 
combined RT and Bps (10 months administration). 
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Standard management for patients with metastatic cancer to 
brain include comfort measures using medications such as 
dexamethasone.  Depending on patient factors (such as 
performance status) and metastatic disease extent, standard 
established local brain treatment includes surgery (for 
resectable single brain metastasis) and radiosurgery (for 
small metastatic disease to brain).  For extensive brain 
metastases and for patients who are not eligible for surgery 
or radiosurgery, whole brain radiotherapy is commonly used. 
The experimental strategy of simultaneous in-field/ 
integrated boost and a summary of newer systemic therapies 
used in the management of brain metastases will be 
reviewed. 
Further research is needed to assess whether these new 
technologies in the management of brain metastases improve 
survival and/ or quality of life. 
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In an era of increasing systemic therapy options for the 
management of patients diagnosed with non-small cell lung 
cancer (NSCLC) who are either not suitable for curative 
therapy or who present with metastatic disease, radiation 
therapy (RT) has an established role.  Specifically, 
conventional RT is an effective, well-tolerated and 
inexpensive treatment modality for the palliation of 
symptoms caused by locally advanced intrathoracic disease or 
arising due to systemic metastases (1). Technological 
advances, specifically the availability of stereotactic RT has 
offered the radiation oncologist a choice in mode of radiation 
delivery.  Stereotactic radiosurgery (SRS) is an increasingly 
important technique in the management of cerebral 
metastases and Stereotactic body RT (SBRT) is being offered 
to patients with oligometastatic disease.  There is no 
evidence to suggestion the SBRT offers outcomes superior to 
those achieve with conventionally fractionated RT although 
this question is being addressed in clinical trials. .  In 
addition, an emerging role for Stereotactic body RT (SBRT) in 
patients with oligometastatic disease is being postulated.  
SBRT by achieving good local control at metastatic sites may 
delay the time until further systemic therapy is warranted.   
